title: Blood pressure, fludrocortisone dose and plasma renin activity in children with classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency followed from birth to 4 years of age.
abstract: BACKGROUND
  Infants with congenital adrenal hyperplasia (CAH) require higher doses of fludrocortisone (FC) due to physiological mineralocorticoid resistance. The adequacy of mineralocorticoid replacement should be closely monitored to avoid hypertension.
  
  
  OBJECTIVE
  To evaluate blood pressure (BP) in infants with CAH due to 21-hydroxylase deficiency.
  
  
  METHODS
  Thirty-three patients (18f/15 m) diagnosed by newborn screening were followed until the age of 4 years. Mean start of HC and FC treatment was day 9·8 ± 9·2 postnatally. Mean daily HC dose ranged from 8·6 to 12·3 mg/m(2) /day.
  
  
  RESULTS
  During the first year of life prevalence of systolic hypertension was up to 45·5%. At 12 and at 18 months, BP was highest. Prevalence of systolic hypertension was up to 57·6% at 18 months of age. After 24 months BP levels were lower and at 48 months prevalence of hypertension decreased to 15·2%. Systolic and diastolic BP correlated significantly with the administered fludrocortisone dose (r = 0·3, P = 0·005), but not with body mass index. Hypertensive children received significantly higher FC doses and had significantly lower plasma renin activity during the study period.
  
  
  CONCLUSIONS
  High prevalence of transient, most likely FC induced hypertension was found in young children with classic CAH diagnosed by newborn screening. The changing mineralocorticoid sensitivity in infants is a risk factor for the development of hypertension in patients with CAH, who are treated with FC. Therefore suppressed plasma renin activity should be avoided to prevent arterial hypertension.
authors.affiliation: Division of Pediatric Endocrinology & Diabetology, Department of Pediatrics, Technische Universität München, Munich, Germany; Division of Pediatric Endocrinology & Diabetology, Department of Pediatrics, Ludwig Maximilian Universität München, Munich, Germany.
authors.forename: Walter
authors.initials: W
authors.lastname: Bonfig
authors.forename: Hans Peter
authors.initials: HP
authors.lastname: Schwarz
mesh_terms: D000312:Adrenal Hyperplasia, Congenital / Q000188:drug therapy* / Q000378:metabolism; D001794:Blood Pressure; D002675:Child, Preschool; D057075:Enzyme Assays; D005260:Female; D005438:Fludrocortisone / Q000008:administration & dosage / Q000009:adverse effects*; D005938:Glucocorticoids / Q000008:administration & dosage / Q000009:adverse effects*; D020249:Hormone Replacement Therapy / Q000009:adverse effects*; D006801:Humans; D006973:Hypertension / Q000139:chemically induced*; D007223:Infant; D007231:Infant, Newborn; D008297:Male; D011863:Radioimmunoassay; D012083:Renin / Q000187:drug effects / Q000378:metabolism*
chemical_list: D005938:Glucocorticoids; D012083:Renin; D005438:Fludrocortisone